Filana Receives Nasdaq Delisting Notice After 30 Days Below $1.00
FLNA is trading near its 52-week low of $0.67 (8.3% above the low) on light trading volume (0.4× avg).
Summary
Nasdaq notified Filana on September 17, 2026 that its stock has traded below $1.00 for 30 consecutive days, triggering a minimum bid price deficiency. The company has until March 16, 2027 to regain compliance or face potential delisting.
Key Events · Legal and Risk Events · FLNA
-
Nasdaq Minimum Bid Price Deficiency
Nasdaq notified Filana on September 17, 2026 that its common stock closed below $1.00 for 30 consecutive business days, violating Listing Rule 5550(a)(2).
-
180-Day Compliance Window
Filana has until March 16, 2027 to regain compliance by closing at or above $1.00 for at least 10 consecutive business days.
-
Potential Second Compliance Period
If not compliant by March 16, 2027, Filana may qualify for a second 180-day period; failure to cure could lead to Nasdaq delisting proceedings.
-
Price Recovery Required
At $0.726 per share as of this report, the stock needs to rise approximately 38% to reach the $1.00 threshold.
Analysis · FLNA · Life Sciences
Filana Therapeutics disclosed on September 18, 2026 that Nasdaq notified the company on September 17, 2026 that its stock had closed below the $1.00 minimum bid price for 30 consecutive business days, triggering a listing deficiency under Rule 5550(a)(2). The stock continues to trade on the Nasdaq Capital Market under FLNA, and the company has 180 calendar days — until March 16, 2027 — to regain compliance by closing at or above $1.00 for at least 10 consecutive business days. If it fails, a second 180-day period may be available, after which Nasdaq could initiate delisting proceedings. With the stock at $0.726 as of this report, the company needs a roughly 38% price recovery to clear the threshold. The company stated it will monitor the bid price and may consider available options, but offered no assurance of success. This is a material listing-risk event for a company that reported $82.7 million in cash as of Q2 2026 — ample runway, but a delisting would severely impair liquidity and institutional access.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 49.5% of the 190 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FLNA was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.1M. The 52-week trading range was $0.67 to $4.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.